PharmTech Drug Digest 11.20
News|Articles|November 11, 2015

TrakCel Ltd. Adds Cognate BioSevices to Connected Services Program

TrakCel Ltd., a cell therapy process management and supply chain integration technology, recently introduced Cognate BioServices as the newest member of its Connected Service program, according to a Nov. 10, 2015 press release. 

Cognate Bioservices is a fully integrated contract bioservices organization providing development and cGMP-manufacturing services to institutions engaged in the development of cell-based products.

The Connected Services partner ecosystem accelerates cell therapy success by enhancing TrakCel's cell therapy supply chain management platform, according to TrakCel. This improvement to the platform supports therapy success by providing links to participant firms specializing in logistics, cell therapy manufacturing, patient treatment, storage, and compliance.

TrakCel’s technology provides additional transparency into the entire cell therapy process, while providing real-time audit logs and chain-of-custody records of critical components.

Source: TrakCel


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.